Workflow
Outset Medical(OM)
icon
Search documents
Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference
Globenewswire· 2025-02-24 21:03
SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors ...
Outset Medical(OM) - 2024 Q4 - Earnings Call Transcript
2025-02-20 01:54
Outset Medical, Inc. (NASDAQ:OM) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-on ...
Outset Medical: Profitability Path Brightens
The Motley Fool· 2025-02-19 23:22
Core Insights - Outset Medical reported fourth-quarter earnings that exceeded analysts' expectations, with revenue of $29.5 million surpassing the forecast of $28 million, indicating resilience in revenue growth despite market challenges [2][3] - The company achieved significant improvements in operational efficiency and gross margins, with adjusted gross margin reaching 37.7%, up from 27.1% year-over-year [4][7] Financial Performance - Adjusted EPS loss was $0.37, better than the projected loss of $0.44, and a significant improvement from the loss of $0.54 in Q4 2023 [4] - Net revenue decreased by 3.3% year-over-year from $30.5 million in Q4 2023 to $29.5 million in Q4 2024 [4] - Adjusted net loss was $19.3 million, an improvement from the $27 million loss in the previous year [4] Business Model and Strategy - Outset Medical is known for its Tablo Hemodialysis System, which simplifies dialysis treatment and reduces costs, with a focus on increasing market penetration in acute and home settings [5][6] - The company is enhancing its sales strategies and customer support to broaden the adoption of the Tablo system [6] Operational Highlights - Gross margin improved significantly due to higher average selling prices for consoles and reduced operational costs [7] - Recurring revenue from consumables and services grew by 17% year-over-year, indicating a shift towards sustainable revenue generation [8] - Operating expenses were reduced by 28% year-over-year, contributing to the pathway to profitability [8] Future Outlook - Management anticipates continued improvements in gross margins, aiming for non-GAAP gross margins in the high-30% range [9] - Revenue projections for 2025 estimate growth between $115 million and $125 million, reflecting confidence in market expansion [9] - The company plans to reduce cash usage to under $50 million, enhancing its financial position for future initiatives [10]
Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates
ZACKS· 2025-02-19 23:15
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.95%. A quarter ago, it was expected that this company would post a loss of $0.42 per share when it actually produced a loss of $0.39, delivering a surprise of 7.14%.Over the last four quarters, the company has surpas ...
Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Newsfilter· 2025-02-19 21:03
SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5 ...
Outset Medical Announces Resolution of Warning Letter
Globenewswire· 2025-02-13 21:35
SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced it has been notified by the Food and Drug Administration that all issues cited in a Warning Letter the company received in July of 2023 have been addressed. “A commitment to innovation and the advancement of better outcomes in dialysis remains at the core of Outset, which makes t ...
Outset Medical, Inc. (OM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ZACKS· 2025-02-12 16:07
Outset Medical, Inc. (OM) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...
Osisko Metals Begins 2025 Drill Program at Gaspé Copper
Globenewswire· 2025-02-10 13:00
Core Viewpoint - Osisko Metals Incorporated has initiated a 110,000-meter drill program at its Gaspé Copper project, aiming to convert inferred resources into indicated or measured categories and explore potential resource expansion [2][4]. Group 1: Drill Program Details - The 2025 drill program is designed to convert existing inferred resources into indicated or measured resource categories, test for deeper resource expansion, characterize higher grade skarn zones, and validate new geological models [2]. - Approximately 10,000 meters of drilling will be conducted outside the main mining concession to explore regional targets [2]. - The first drill began operations last week, with drilling expected to conclude by November 2025, and additional drills will be added as needed [3]. Group 2: Company Overview - Osisko Metals is focused on the critical metals sector, particularly copper and zinc, and acquired a 100% interest in the Gaspé Copper mine from Glencore Canada Corporation in July 2023 [4]. - The Gaspé Copper project has current Indicated Mineral Resources of 824 million tonnes grading 0.34% CuEq and Inferred Mineral Resources of 670 million tonnes grading 0.38% CuEq [4]. - The Gaspé Copper project is noted for hosting the largest undeveloped copper resource in eastern North America, strategically located near existing infrastructure [4]. Group 3: Other Projects - In addition to the Gaspé Copper project, the company is advancing the Pine Point project, which is one of Canada's largest past-producing zinc mining camps, through a joint venture with Appian Capital Advisory LLP [5]. - The Pine Point project has current Indicated Mineral Resources of 49.5 million tonnes at 5.52% ZnEq and Inferred Mineral Resources of 8.3 million tonnes at 5.64% ZnEq [5].
Kuehn Law Encourages Investors of Outset Medical, Inc. to Contact Law Firm
Newsfilter· 2025-02-06 22:52
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Outset Medical, Inc. (NASDAQ:OM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Outset insiders caused the company to misrepresent or fail to disclose that (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) that, as a resul ...
Outset Medical to Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, February 19, 2025
GlobeNewswire News Room· 2025-02-03 14:00
Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [4] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [4] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [4] Financial Results Announcement - Outset Medical will release financial results for the fourth quarter and full-year 2024 after the close of trading on February 19, 2025 [1] - A conference call will be hosted by Leslie Trigg, Chair and CEO, and Nabeel Ahmed, CFO, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day to discuss financial and operating results [2][3] Conference Call Details - Participants interested in joining the conference call must register online to receive dial-in numbers and a unique pin [3] - It is encouraged for participants to register more than 15 minutes before the start of the call [3] - A live and archived webcast of the event will be available on the "Investors" section of the Outset website [3]